PL2608789T5 - Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny - Google Patents

Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny

Info

Publication number
PL2608789T5
PL2608789T5 PL11749331.2T PL11749331T PL2608789T5 PL 2608789 T5 PL2608789 T5 PL 2608789T5 PL 11749331 T PL11749331 T PL 11749331T PL 2608789 T5 PL2608789 T5 PL 2608789T5
Authority
PL
Poland
Prior art keywords
dimethylphenylsulfanyl
piperazine
phenyl
therapeutic uses
therapeutic
Prior art date
Application number
PL11749331.2T
Other languages
English (en)
Polish (pl)
Other versions
PL2608789T3 (pl
Inventor
Marianne Dragheim
Ioana Florea
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2608789(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of PL2608789T3 publication Critical patent/PL2608789T3/pl
Publication of PL2608789T5 publication Critical patent/PL2608789T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11749331.2T 2010-08-23 2011-08-22 Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny PL2608789T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (2)

Publication Number Publication Date
PL2608789T3 PL2608789T3 (pl) 2017-09-29
PL2608789T5 true PL2608789T5 (pl) 2025-11-12

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11749331.2T PL2608789T5 (pl) 2010-08-23 2011-08-22 Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny

Country Status (32)

Country Link
US (5) US20130184291A1 (enExample)
EP (1) EP2608789B2 (enExample)
JP (1) JP5902169B2 (enExample)
KR (1) KR101816953B1 (enExample)
CN (1) CN103068389A (enExample)
AP (1) AP3583A (enExample)
AR (1) AR082501A1 (enExample)
AU (1) AU2011295465B8 (enExample)
BR (2) BR122020025600A2 (enExample)
CA (1) CA2807062C (enExample)
CL (1) CL2013000492A1 (enExample)
CO (1) CO6680652A2 (enExample)
CY (1) CY1118886T1 (enExample)
DK (1) DK2608789T4 (enExample)
ES (1) ES2625142T5 (enExample)
FI (1) FI2608789T4 (enExample)
HR (1) HRP20170608T4 (enExample)
HU (1) HUE034155T2 (enExample)
IL (1) IL224371A (enExample)
LT (1) LT2608789T (enExample)
ME (1) ME02674B (enExample)
MX (1) MX349724B (enExample)
PL (1) PL2608789T5 (enExample)
PT (1) PT2608789T (enExample)
RS (1) RS55851B2 (enExample)
RU (1) RU2564666C2 (enExample)
SG (1) SG187649A1 (enExample)
SI (1) SI2608789T2 (enExample)
SM (1) SMT201700239T1 (enExample)
TW (1) TW201212918A (enExample)
WO (1) WO2012025123A1 (enExample)
ZA (1) ZA201301385B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ES2087463T3 (es) * 1991-11-18 1996-07-16 Lilly Industries Ltd Benzo(b)tiofen-2-carboxamidas para el tratamiento de trastornos del sistema nervioso central.
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
WO2002029232A1 (en) 2000-10-02 2002-04-11 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
HUE034155T2 (en) 2018-01-29
BR122020025600A2 (pt) 2021-01-05
US20190000836A1 (en) 2019-01-03
KR20130097162A (ko) 2013-09-02
JP5902169B2 (ja) 2016-04-13
AU2011295465A1 (en) 2013-02-07
JP2013536206A (ja) 2013-09-19
RS55851B1 (sr) 2017-08-31
RU2013112890A (ru) 2014-09-27
SI2608789T2 (sl) 2025-05-30
RS55851B2 (sr) 2024-11-29
TW201212918A (en) 2012-04-01
HRP20170608T4 (hr) 2024-12-06
PT2608789T (pt) 2017-05-26
DK2608789T4 (da) 2024-11-04
US20220370439A1 (en) 2022-11-24
ES2625142T5 (en) 2025-02-10
LT2608789T (lt) 2017-05-25
ZA201301385B (en) 2014-04-30
AU2011295465B2 (en) 2014-06-19
IL224371A (en) 2016-07-31
CL2013000492A1 (es) 2013-06-07
MX2013001570A (es) 2013-03-21
RU2564666C2 (ru) 2015-10-10
WO2012025123A1 (en) 2012-03-01
KR101816953B1 (ko) 2018-01-09
PL2608789T3 (pl) 2017-09-29
CN103068389A (zh) 2013-04-24
EP2608789A1 (en) 2013-07-03
US20130184291A1 (en) 2013-07-18
EP2608789B2 (en) 2024-08-21
SI2608789T1 (sl) 2017-06-30
SG187649A1 (en) 2013-03-28
AP2013006768A0 (en) 2012-03-31
AP3583A (en) 2016-02-09
US20210085674A1 (en) 2021-03-25
DK2608789T3 (en) 2017-05-15
SMT201700239T1 (it) 2017-07-18
CO6680652A2 (es) 2013-05-31
AR082501A1 (es) 2012-12-12
ES2625142T3 (es) 2017-07-18
CY1118886T1 (el) 2018-01-10
FI2608789T4 (fi) 2024-11-01
MX349724B (es) 2017-08-10
HRP20170608T1 (hr) 2017-07-28
CA2807062C (en) 2018-07-31
AU2011295465B8 (en) 2014-07-10
CA2807062A1 (en) 2012-03-01
US20240293397A1 (en) 2024-09-05
EP2608789B1 (en) 2017-04-12
ME02674B (me) 2017-06-20
BR112013002194A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
CO7000771A2 (es) Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
IL214178A0 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine
IL215362A0 (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
HRP20160658T1 (hr) Novi pirolni inhibitori reduktaze s-nitrozoglutationa kao terapeutska sredstva
ITMI20111404A1 (it) Supporto per articolazioni umane.
ZA201201360B (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
EP2643000A4 (en) THERAPEUTIC PIPERAZINES
EP2656872A4 (en) ELECTRODE PAD FOR IONTOPHORESIS
EP2701589A4 (en) electrode applicator
CO6880070A2 (es) Dosis combinada fija de bimatoprost y brimonidina
IT1402399B1 (it) Canna perfezionata.
BR112013010643A2 (pt) compostos heterocíclicos
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
PL395785A1 (pl) Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu
DK2593381T3 (da) Medicinsk forbrugsvare-emballage
HUE043092T2 (hu) Eljárás l-[2-(2,4-dimetil-fenilszulfanil)-fenil]-piperazin elõállítására
UA21850S (uk) Ліжко «діана»